Haleon (HLN) said in a regulatory filing Friday it has completed the acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical, the company's joint venture in China, for 1.62 billion Chinese renminbi ($226.4 million).
According to the company, the deal will allow it to drive category growth in one of the fastest-growing OTC markets globally.
As a result of the transaction, Tianjin TSKF Pharmaceutical is now a wholly-owned subsidiary of Haleon, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。